Neovacs, a leading biotechnology company in the development of anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases, announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNF
Navigation
Daily News
- Cardiac Catheterizations: Too Many Performed?
- Salmonella Risk Prompts Wider Food Recall
- Diamyd Medical: Diamyd US Phase III Study Well Under Way
- WHO Releases New Malaria Guidelines For Treatment And Procurement Of Medicines
- ONC Publishes EHR Certification Rule
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  | ||
| By N2H | |||||||||